Dr. Melissa A. Burgess
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Expert in Sarcoma
Studies Soft Tissue Sarcoma
23 reported clinical trials
42 drugs studied
About Melissa A. Burgess
Education:
- Obtained a BS in Biochemistry & Molecular Biology and Chemistry from Dickinson College in 2005.
- Earned an MD from Drexel University College of Medicine in 2009.
- Completed Internal Medicine Residency at the University of Pittsburgh, UPMC (2009-2012).
- Finished Hematology/Oncology Fellowship at the University of Pittsburgh, UPMC (2012-2015), serving as Chief in 2014.
Experience:
- Serves as Assistant Professor of Medicine at the University of Pittsburgh School of Medicine.
- Acts as a Clinical and Translational Investigator in Sarcoma, with a focus on clinical trials.
- Holds the position of Local Principal Investigator for several clinical trials, including SARC 028 and CITN-09.
- Specializes in the treatment of soft tissue and bone sarcoma patients at the Hillman Cancer Center.
Area of expertise
1Sarcoma
Global LeaderStage IV
Stage III
EWSR1/ATF1 positive
2Soft Tissue Sarcoma
Stage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Melissa A. Burgess is currently running
Atezolizumab +/− Selinexor
for Sarcoma
This trial is testing if atezolizumab alone or with selinexor can shrink tumors in patients with a rare type of cancer called alveolar soft part sarcoma. Atezolizumab boosts the immune system to fight cancer, and selinexor stops cancer cells from growing. The goal is to see if these treatments work better than the usual care.
Recruiting1 award Phase 2
INBRX-109
for Chondrosarcoma
This trial tests INBRX-109, a specially designed protein, in patients with a hard-to-treat type of bone cancer. The treatment helps the immune system target and kill cancer cells by attaching to a specific marker on these cells.
Recruiting0 awards Phase 26 criteria
More about Melissa A. Burgess
Clinical Trial Related4 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Melissa A. Burgess has experience with
- Nivolumab
- Atezolizumab
- Dacarbazine
- Placebo
- Cabozantinib
- YH001
Breakdown of trials Melissa A. Burgess has run
Sarcoma
Soft Tissue Sarcoma
Cancer
Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Melissa A. Burgess specialize in?
Melissa A. Burgess focuses on Sarcoma and Soft Tissue Sarcoma. In particular, much of their work with Sarcoma has involved Stage IV patients, or patients who are Stage III.
Is Melissa A. Burgess currently recruiting for clinical trials?
Yes, Melissa A. Burgess is currently recruiting for 6 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Melissa A. Burgess has studied deeply?
Yes, Melissa A. Burgess has studied treatments such as Nivolumab, Atezolizumab, Dacarbazine.
What is the best way to schedule an appointment with Melissa A. Burgess?
Apply for one of the trials that Melissa A. Burgess is conducting.
What is the office address of Melissa A. Burgess?
The office of Melissa A. Burgess is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.